AST follicular phase
Selected indexed studies
- The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study. (Hemasphere, 2024) [PMID:39108321]
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. (Cancer Sci, 2010) [PMID:20491780]
- Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. (Am J Hematol, 2020) [PMID:32052473]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. (2021) pubmed
- Rhythmic Fluctuations in Levels of Liver Enzymes During Menstrual Cycles of Healthy Women and Effects of Body Weight. (2020) pubmed
- Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma. (2020) pubmed
- Serum miRNAs in women affected by hyperandrogenic polycystic ovary syndrome: the potential role of miR-155 as a biomarker for monitoring the estroprogestinic treatment. (2018) pubmed
- Effect of dietary supplementation of palm kernel cake on ovarian and hepatic function in buffalo (Bubalus bubalis). (2019) pubmed
- Exercise, sex, menstrual cycle phase, and 17beta-estradiol influence metabolism-related genes in human skeletal muscle. (2009) pubmed
- Influence of estrous stages on electrocardiography, clinical pathology and ovarian weight of experimental beagle dogs: a retrospective analysis. (2019) pubmed
- The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study. (2024) pubmed
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. (2010) pubmed
- Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. (2020) pubmed